{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:21:20Z","timestamp":1780536080106,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.vaccine.2022.01.009","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T12:16:47Z","timestamp":1642594607000},"page":"977-987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants"],"prefix":"10.1016","volume":"40","author":[{"given":"Daniel","family":"Tus\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Malm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Tamminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Diessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Jarczowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Blazevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Klimyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2022.01.009_b0005","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1086\/342386","article-title":"Foodborne viral gastroenteritis: challenges and opportunities","volume":"35","author":"Bresee","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.01.009_b0010","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/cid\/ciu120","article-title":"The state of norovirus vaccines","volume":"58","author":"Debbink","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.009_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2008.10.009","article-title":"Noroviruses: a comprehensive review","volume":"44","author":"Patel","year":"2009","journal-title":"J Clin Virol"},{"issue":"18","key":"10.1016\/j.vaccine.2022.01.009_b0020","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJMra0804575","article-title":"Norovirus gastroenteritis","volume":"361","author":"Glass","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.009_b0025","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ajic.2010.04.196","article-title":"Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, Clostridium difficile, and Acinetobacter species","volume":"38","author":"Weber","year":"2010","journal-title":"Am J Infect Control"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.009_b0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12560-014-9145-5","article-title":"Norovirus outbreaks on commercial cruise ships: a systematic review and new targets for the public health agenda","volume":"6","author":"Bert","year":"2014","journal-title":"Food Environ Virol"},{"key":"10.1016\/j.vaccine.2022.01.009_b0035","first-page":"20","article-title":"Outbreak of norovirus illness in a college summer camp: impact of cleaning on occurrence of norovirus on fomites","volume":"76","author":"Fankem","year":"2014","journal-title":"J Environ Health"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.009_b0040","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/bmjqs-2015-004134","article-title":"Reducing the number and impact of outbreaks of nosocomial viral gastroenteritis: time-series analysis of a multidimensional quality improvement initiative","volume":"25","author":"Mitchell","year":"2016","journal-title":"BMJ Quality Safety"},{"key":"10.1016\/j.vaccine.2022.01.009_b0045","doi-asserted-by":"crossref","unstructured":"Esposito S, Principi N. Norovirus vaccine: priorities for future research and development. Front Immunol 2020;11. .","DOI":"10.3389\/fimmu.2020.01383"},{"issue":"50","key":"10.1016\/j.vaccine.2022.01.009_b0050","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1016\/j.vaccine.2016.10.090","article-title":"Report from the World Health Organization\u2019s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8\u201310th June 2016","volume":"37","author":"Giersing","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.009_b0055","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2014.2","article-title":"Histo-blood group antigens: a common niche for norovirus and rotavirus","volume":"16","author":"Tan","year":"2014","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.vaccine.2022.01.009_b0060","doi-asserted-by":"crossref","unstructured":"Clausen H, Hakornori S-I, ABH and Related Histo-Blood Group Antigens. Immunochemical differences in carrier isotypes and their distribution. 1989;56.","DOI":"10.1159\/000460912"},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.009_b0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0300-9084(01)01321-9","article-title":"ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world","volume":"83","author":"Marionneau","year":"2001","journal-title":"Biochimie"},{"issue":"10","key":"10.1016\/j.vaccine.2022.01.009_b0070","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1099\/jgv.0.001318","article-title":"Updated classification of norovirus genogroups and genotypes","volume":"100","author":"Chhabra","year":"2019","journal-title":"J Gen Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2022.01.009_b0075","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00705-013-1708-5","article-title":"Proposal for a unified norovirus nomenclature and genotyping","volume":"158","author":"Kroneman","year":"2013","journal-title":"Arch Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.009_b0080","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/JCM.02680-13","article-title":"Genotypic and epidemiologic trends of norovirus outbreaks in the united states, 2009 to 2013","volume":"52","author":"Vega","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2022.01.009_b0085","doi-asserted-by":"crossref","unstructured":"Chan MCW, Shan Kwan H, Chan PKS. Structure and genotypes of noroviruses. The Norovirus, Elsevier; 2017. doi: 10.1016\/B978-0-12-804177-2.00004-X.","DOI":"10.1016\/B978-0-12-804177-2.00004-X"},{"key":"10.1016\/j.vaccine.2022.01.009_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.femsle.2005.08.031","article-title":"Norovirus protein structure and function","volume":"253","author":"Hardy","year":"2005","journal-title":"FEMS Microbiol Lett"},{"issue":"26","key":"10.1016\/j.vaccine.2022.01.009_b0095","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.vaccine.2016.03.077","article-title":"Status of vaccine research and development for norovirus","volume":"34","author":"Riddle","year":"2016","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.01.009_b0100","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/infdis\/jiu337","article-title":"A novel intramuscular bivalent norovirus viruslike particle vaccine candidate-reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults","volume":"210","author":"Treanor","year":"2014","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.009_b0105","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/infdis\/jiw259","article-title":"Rapid responses to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: a randomized controlled trial","volume":"214","author":"Atmar","year":"2016","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.009_b0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/infdis\/jix572","article-title":"Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial","volume":"217","author":"Leroux-Roels","year":"2018","journal-title":"J Infect Dis"},{"issue":"41","key":"10.1016\/j.vaccine.2022.01.009_b0115","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1016\/j.vaccine.2020.07.069","article-title":"Efficacy of an intramuscular bivalent norovirus GI.1\/GII.4 virus-like particle vaccine candidate in healthy US adults","volume":"38","author":"Sherwood","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.009_b0120","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy210.1929","article-title":"Immunogenicity of takeda\u2019s bivalent virus-like particle (VLP) norovirus vaccine (NoV) candidate in children from 6 months up to 4 years of age","volume":"5","author":"Masuda","year":"2018","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1016\/j.vaccine.2022.01.009_b0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coviro.2017.07.019","article-title":"Using transgenic plants and modified plant viruses for the development of treatments for human diseases","volume":"26","author":"Loh","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2022.01.009_b0130","doi-asserted-by":"crossref","unstructured":"Tus\u00e9 D, Nandi S, McDonald KA, Buyel JF. The emergency response capacity of plant-based biopharmaceutical manufacturing-what it is and what it could be. Front Plant Sci 2020;11. .","DOI":"10.3389\/fpls.2020.594019"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.009_b0135","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/bfgp\/ely020","article-title":"Vaccine and antibody production in plants: developments and computational tools","volume":"17","author":"Dubey","year":"2018","journal-title":"Briefings Funct Genomics"},{"key":"10.1016\/j.vaccine.2022.01.009_b0140","doi-asserted-by":"crossref","unstructured":"Rosales-Mendoza S, M\u00e1rquez-Escobar VA, Gonz\u00e1lez-Ortega O, Nieto-G\u00f3mez R, Ar\u00e9valo-Villalobos JI. What does plant-based vaccine technology offer to the fight against COVID-19? Vaccines 2020;8. doi: 10.3390\/vaccines8020183.","DOI":"10.3390\/vaccines8020183"},{"issue":"5-6","key":"10.1016\/j.vaccine.2022.01.009_b0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/2051013615613272","article-title":"Plant-based vaccines for animals and humans: recent advances in technology and clinical trials","volume":"3","author":"Takeyama","year":"2015","journal-title":"Ther Ad Vaccines"},{"issue":"1-2","key":"10.1016\/j.vaccine.2022.01.009_b0150","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drudis.2008.10.002","article-title":"Plant-produced vaccines: promise and reality","volume":"14","author":"Rybicki","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.vaccine.2022.01.009_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/648143","article-title":"Clinical safety and immunogenicity of tumor-targeted, plant-made Id-KLH conjugate vaccines for follicular lymphoma","volume":"2015","author":"Tus\u00e9","year":"2015","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.009_b0160","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/pharmaceutics11050229","article-title":"Rotavirus VP6 as an adjuvant for bivalent norovirus vaccine produced in Nicotiana benthamiana","volume":"11","author":"Malm","year":"2019","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.009_b0165","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nbt1094","article-title":"Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants","volume":"23","author":"Marillonnet","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2022.01.009_b0170","doi-asserted-by":"crossref","unstructured":"Klimyuk V, Pogue G, Herz S, Butler J, Haydon H. Production of recombinant antigens and antibodies in Nicotiana benthamiana using \u2018Magnifection\u2019 Technology: GMP-compliant facilities for small- and large-scale manufacturing. 2012. doi: 10.1007\/82_2012_212.","DOI":"10.1007\/82_2012_212"},{"key":"10.1016\/j.vaccine.2022.01.009_b0175","unstructured":"EMEA CPMP\/SWP465\/95. Note for guidance on preclinical pharmacological and toxicological testing of vaccines; 1997."},{"key":"10.1016\/j.vaccine.2022.01.009_b0180","unstructured":"World Health Organization. WHO guidelines on nonclinical evaluation of vaccines; 2005."},{"key":"10.1016\/j.vaccine.2022.01.009_b0185","unstructured":"FDA. Guidance for Industry: Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications; 2006."},{"key":"10.1016\/j.vaccine.2022.01.009_b0190","unstructured":"International Conference on Harmonization. ICH M3(R2) guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals; 2009."},{"key":"10.1016\/j.vaccine.2022.01.009_b0195","unstructured":"International Conference on Harmonization. ICH guideline S6(R1) \u2013 preclinical safety evaluation of biotechnology-derived pharmaceuticals; 2011."},{"key":"10.1016\/j.vaccine.2022.01.009_b0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-3565(25)08751-8","article-title":"Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes","volume":"82","author":"Draize","year":"1944","journal-title":"J Pharmacol Exp Therap"},{"issue":"45","key":"10.1016\/j.vaccine.2022.01.009_b0205","doi-asserted-by":"crossref","first-page":"8126","DOI":"10.1016\/j.vaccine.2011.08.026","article-title":"Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis","volume":"29","author":"Blazevic","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.009_b0210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2567.2011.03516.x","article-title":"A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles","volume":"135","author":"Tamminen","year":"2012","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.vaccine.2022.01.009_b0215","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cei.12977","article-title":"Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs","volume":"189","author":"Malm","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.009_b0220","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/JVI.06200-11","article-title":"Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002","volume":"86","author":"Lindesmith","year":"2012","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.009_b0225","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.micinf.2014.02.010","article-title":"Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assays","volume":"16","author":"Uusi-Kerttula","year":"2014","journal-title":"Microbes Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2022.01.009_b0230","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4161\/hv.7.3.14213","article-title":"Safety of plant-made pharmaceuticals: product development and regulatory considerations based on case studies of two autologous human cancer vaccines","volume":"7","author":"Tus\u00e9","year":"2011","journal-title":"Human Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.009_b0235","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/v11020151","article-title":"Human norovirus: experimental models of infection","volume":"11","author":"Todd","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2022.01.009_b0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.molimm.2016.08.009","article-title":"Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein","volume":"78","author":"Malm","year":"2016","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.01.009_b0245","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/00365540110080881","article-title":"A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of engerix-B in healthy young adults","volume":"34","author":"Levie","year":"2002","journal-title":"Scand J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:09:09Z","timestamp":1759403349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22000226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0264410X22000226"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}